Buprenorphine prescription patterns in a county correctional facility: patient population and post-release outcomes

Zachary Lenane, MD, MPH; Darryl Liu, LCSW; Andrea N. Ponce, BA; Cynthia Chatterjee, MD; Tasha Souter, MD; Rachel Loewy, PhD



Background

- Opioid overdose is a leading cause of death during immediate re-entry period after incarceration for those with opioid use disorder (OUD).
- Adjusted RR up to 129 that of nonincarcerated individuals with OUD.
- Re-entry buprenorphine (bup) reduces overdose deaths by 60%.²
- Slow adoption of bup in correctional systems due to concerns about diversion, stigma related to treatment, and logistics.³
- Aim to conduct first formal assessment of new correctional health bup program.

Setting

- San Mateo County, CA Correctional Health Services (CHS)
- 2020: Began prescribing bup maintenance in two county jails
- CHS coordinates with Behavioral Health & Recovery Services' (BHRS) Integrated Medication Assisted Treatment (IMAT) program to link county residents to outpatient treatment upon release.


Objectives

- Provide data on impact of new county correctional system bup program on health and criminal justice outcomes.
- Identify populations needing more intensive interventions for future program development.
- Strengthen the BHRS-CHS partnership.

Methods

- **Design:** Retrospective cohort analysis
- Data Source: County EHR

- Sample: 162 individuals incarcerated in San Mateo County during the first year of active bup prescribing (Oct 2020 Oct 2021) who self-reported opioid use.
- Median age=31, 83% male, median days incarcerated=51
- 46% White, 25% Black, 22% Hispanic/Latinx, 4% Other
- **Procedures:** Examined bup prescription in jail and postrelease outcomes (bup prescription, outpatient and emergency service utilization, reincarceration).
- Analysis: Compared baseline characteristics and postrelease outcomes between those prescribed bup vs not
 using two-sample t-tests or Wilcoxon rank-sum tests for
 continuous variables, and Chi-square/Fisher's exact tests for
 categorical variables. All data was analyzed using Stata/IC
 15.1. This study was approved by UCSF and SMC BHRS
 IRB Committees.



Results

- 91% placed on COWS protocol within a day
- No difference in bup prescription by age, race/ethnicity, gender, county of referral, time incarcerated
- 9 reincarcerated during the study period
- 47 out of 162 (29%) were SMC residents referred to IMAT upon release





Figure 2: Post-release care connection for SMC residents (N=47)



- 3/5 people had clinic visits and bup rx ≤ week, 2 were 200+ days after release
 - 2/3 received bup while incarcerated
- 1 had f/u ≤ week, 1 200+ days after release
- 15 emergency visits (14 ED, 1 PES) by 9 patients during
 12 month f/u
 - Median days to first ED visit=123
- 4 SMC residents reincarcerated (1 received bup during first incarceration, 0 connected to outpatient care)

Discussion

- During first year of CHS bup prescription:
 - Quick opioid use screening of new inmates
 - Equitable bup prescription
 - Many referrals for outpatient care on release
- Core staffing levels impacted bup prescription.
- Significant IMAT and CHS coordination and referral efforts included in-person and virtual visits with IMAT case manager prior to release.
- Very few patients (6.5%) connected with outpatient care during high-risk re-entry period.
- All successful IMAT connections were prescribed bup.
- Limited published literature on expected rates of post-release bup.
- Recommend additional study examining barriers to care and patient interest in services during the first month of release.

Limitations:

- Unknown how many inmates met OUD criteria, were offered bup but refused.
- Data unavailable on 40% of inmates prescribed bup:
 - Released with bup in their property and given IMAT flyers without formal referral
 - ~11/2021 to 3/2021, decreased over study period
- Bup protocol changed throughout study period due to continuous practice improvements:
 - Amount prescribed increased over Nov 2021 to Feb 2022
 - Referral protocol changed over time
 - Data do not reflect current practices

Acknowledgements

This project was supported by San Mateo County Health, UCSF Public Psychiatry Fellowship at Zuckerberg San Francisco General Hospital. We thank Matt Boyle, CPRP; Christina Mangurian, MD, MAS; Jim Dilley, MD; N Kyle Jamison, MD; Lisa R. Fortuna, MD, MPH, M.Div.

References

- 1. Binswanger, I. A., Stern, M. F., Deyo, R. A., Heagerty, P. J., Cheadle, A., Elmore, J. G., & Koepsell, T. D. (2007). Release from prison--a high risk of death for former inmates. The New England journal of medicine, 356(2), 157–165. https://doi.org/10.1056/NEJMsa064115.
- 2. Green, T. C., Clarke, J., Brinkley-Rubinstein, L., Marshall, B., Alexander-Scott, N., Boss, R., & Rich, J. D. (2018). Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System. JAMA psychiatry, 75(4), 405–407. https://doi.org/10.1001/jamapsychiatry.2017.4614.
- 3. Friedmann, P. D., Hoskinson, R., Gordon, M., Schwartz, R., Kinlock, T., Knight, K., Flynn, P. M., Welsh, W. N., Stein, L. A., Sacks, S., O'Connell, D. J., Knudsen, H. K., & Mat Working Group Of CJ-Dats (2012). Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Substance abuse, 33(1), 9–18. https://doi.org/10.1080/08897077.2011.611460.